Published in Biomed Pharmacother on July 05, 2007
Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol (2009) 2.65
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol (2010) 1.08
[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation. Am J Respir Crit Care Med (2009) 1.07
The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clin Exp Immunol (2011) 0.84
The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats. J Neural Transm (Vienna) (2011) 0.81
Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation. J Immunol (2009) 0.81
Statins inhibit monocyte chemotactic protein 1 expression in endometriosis. Reprod Sci (2012) 0.80
Brain Oxidative Stress During Experimental Sepsis Is Attenuated by Simvastatin Administration. Mol Neurobiol (2016) 0.77
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci U S A (2010) 1.90
HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol (2010) 1.38
NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression. J Immunol (2012) 1.29
Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III. J Immunol (2002) 1.25
Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. Am J Hum Genet (2011) 1.24
Epigenetics in atherosclerosis and inflammation. J Cell Mol Med (2010) 1.21
NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol (2012) 1.17
Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J (2009) 1.14
Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation. J Neuroinflammation (2012) 1.09
Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol (2009) 1.09
Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J Immunol (2005) 1.09
E47, IRF-4, and PU.1 synergize to induce B-cell-specific activation of the class II transactivator promoter III (CIITA-PIII). Blood (2004) 1.05
Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects. Eur J Hum Genet (2013) 1.02
Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34-56 peptide in incomplete adjuvant. Eur J Immunol (2011) 0.98
CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis. J Neuropathol Exp Neurol (2003) 0.96
Structural and functional differences between the promoters of independently expressed killer cell Ig-like receptors. Eur J Immunol (2005) 0.94
HLA-G transactivation by cAMP-response element-binding protein (CREB). An alternative transactivation pathway to the conserved major histocompatibility complex (MHC) class I regulatory routes. J Biol Chem (2002) 0.94
CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood (2008) 0.94
Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies. CNS Neurol Disord Drug Targets (2011) 0.93
Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer (2002) 0.92
Regulation of MHC class II expression in human T-cell malignancies. Blood (2003) 0.92
Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors. J Cell Mol Med (2012) 0.92
Epigenetic silencing of MHC2TA transcription in cancer. Biochem Pharmacol (2006) 0.91
Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. J Immunol (2010) 0.89
Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol (2005) 0.87
Lack of MHC-II expression in activated mouse T cells correlates with DNA methylation at the CIITA-PIII region. Immunogenetics (2005) 0.85
Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest Ophthalmol Vis Sci (2005) 0.84
Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. Int Immunol (2004) 0.83
Hantaviral mechanisms driving HLA class I antigen presentation require both RIG-I and TRIF. Eur J Immunol (2013) 0.81
Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. Am J Pathol (2009) 0.81
Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines. Ann N Y Acad Sci (2009) 0.81
Epigenetic regulation of CIITA expression in human T-cells. Biochem Pharmacol (2011) 0.79
The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. Hum Immunol (2005) 0.79
Statins and control of MHC2TA gene transcription. Nat Med (2005) 0.78
Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not? Am J Pathol (2003) 0.78
Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines. Apoptosis (2014) 0.77
Simvastatin affects cell motility and actin cytoskeleton distribution of microglia. Glia (2006) 0.77
Transcriptional silencing of RFXAP in MHC class II-deficiency. Mol Immunol (2008) 0.77
Constitutive and IFNgamma-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region. Mol Immunol (2006) 0.76
Pre-term birth and severe pre-eclampsia are not associated with altered expression of HLA on human trophoblasts. Am J Reprod Immunol (2003) 0.75
Bringing antigens to attention: a conspiracy of genes, proteins and cells. Curr Opin Immunol (2010) 0.75